Biotech bill's provisions are blurry
Effect on companies from out of state may prove to be limited
When House lawmakers unveiled the latest version of the state's $1 billion life-sciences bill last week, a new wrinkle caught some Patrick administration and industry officials by surprise. (Full article: 578 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
